![Liu Hui](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: - $ al 31/07/2026
Liu Hui currently works at Rallybio Corp., as Independent Director from 2022.
Dr. Hui also formerly worked at Novartis AG, as VP & Head-Business Development & Licensing from 2013 to 2015 and Merus NV, as Chief Business Officer & Executive Vice President from 2015 to 2024.
Dr. Hui received his undergraduate degree from Peking University and Masters Business Admin degree and doctorate degree from the University of Michigan.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
RALLYBIO CORPORATION -.--% | 19/12/2025 | 0 ( -.--% ) | - $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| RALLYBIO CORPORATION | Director/Miembro de la Junta | 04/04/2022 |
| Empresas | Cargo | Fin |
|---|---|---|
| MERUS N.V. | Corporate Officer/Principal | 01/07/2024 |
| NOVARTIS AG | Corporate Officer/Principal | 01/01/2015 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Peking University
 Peking University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Michigan
 University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merus NV
 Merus NV BiotechnologyHealth Technology Discovers and develops therapeutics for cancer treatment | Health Technology |
Rallybio Corp.
 Rallybio Corp. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that engages in research, development and commercialization of therapies for patients with severe & rare diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
